Risk minimization measures for blood screening HIV-1 nucleic acid amplification technique assays in Germany

Transfusion Medicine and Hemotherapy

Volumn 41, Issue 1, 2014, Pages 45-51

  Chudy, Michael ^a   Kress, Julia ^a   Halbauer, Jochen ^a   Heiden, Margarethe ^a   Funk, Markus B ^a   Nübling, C Micha ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Blood safety; HIV 1 nucleic acid amplification technique; HIV 1 variant

Indexed keywords

NUCLEIC ACID; VIRUS RNA;

ADULT; AMPLICON; ARTICLE; BLOOD COMPONENT; BLOOD DONOR; BLOOD SAFETY; CLINICAL ARTICLE; COMPARATIVE STUDY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FALSE NEGATIVE RESULT; FEMALE; GENE DELETION; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY DIAGNOSIS; MALE; NUCLEIC ACID AMPLIFICATION; NUCLEOTIDE SEQUENCE; POINT MUTATION; RECIPIENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; VIRUS DETECTION; VIRUS GENOME; VIRUS LOAD; VIRUS TRANSMISSION; YOUNG ADULT;

EID: 84928011566     PISSN: 16603796     EISSN: 16603818     Source Type: Journal    
DOI: 10.1159/000357103     Document Type: Article

References (21)

1. European Centre for Disease Prevention and Control: Annual Epidemiological Report 2012. Reporting on 2010 surveillance data and 2011 epidemic intelligence data. Stockholm: ECDC; 2013. www.ecdc.europa.eu/en/publications/Publications/Annual-Epidemiological-Report-2012.pdf.
2. Offergeld R, Ritter S, Quabeck L, Hamouda O: HIV-, HCV-, HBV-und Syphilissurveillance unter Blutspendern in Deutschland 2008-2010. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012;55:907-913.
3. Roth WK, Busch MP, Schuller A, et al.: International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
4. Paul-Ehrlich-Institut. Stufenplan: Verminderung des Risikos von HIV-1-Infektionen durch zelluläre Blutprodukte und gefrorenes Frischplasma Anordnung der Testung auf HIV-1-RNA mit Nukleinsäure-Amplifikationstechniken. Bundesanzeiger 2003;103:12269.
5. Holmes H, Davis C, Heath A, Hewlett I, Lelie N: An international collaborative study to establish the 1st international standard for HIV-1 RNA for use in nucleic acid-based techniques. J Virol Methods 2001;92:141-150.
6. Nübling CM, Chudy M, Löwer J: Validation of HCV-NAT assays and experience with NAT application for blood screening in Germany. Biologicals 1999;27:291-294.
7. Nübling CM, Heiden M, Chudy M, Kress J, Seitz R, Keller-Stanislawski B, Funk MB: Experience of mandatory nucleic acid test (NAT) screening across all blood organizations in Germany: NAT yield versus breakthrough transmissions. Transfusion 2009;49:1850-1858.
8. Schmidt M, Korn K, Nuebling CM, Chudy M, Kress J, Horst HA, Geusendam G, Hennig H, Sireis W, Rabenau H, Doerr HW, Berger A, Hourfar MK, Gubbe K, Karl A, Fickenscher H, Tischer K, Babiel R, Seifried E, Guertler L: First transmission of HIV-1 by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion 2009;49:1836-1844.
9. Edelmann A, Kalus U, Oltmann A, Stein A, Unbehaun A, Drosten C, Kruger DH, Hofmann J: Improvement of an ultrasensitive human immunodeficiency virus type 1 real-time reverse transcriptase-polymerase chain reaction targeting the long terminal repeat region. Transfusion 2010;50: 685-692.
10. Foglieni B, Candotti D, Guarnori I, Raffaele L, Berzuini A, Spreafico M, Orani A, Rossotti R, Rossi D, Allain JP, Prati D: A cluster of human immunodeficiency virus type 1 recombinant form escaping detection by commercial genomic amplification assays. Transfusion 2011;51:719-730.
11. Chudy M, Weber-Schehl M, Pichl L, Jork C, Kress J, Heiden M, Funk MB, Nübling CM: Blood screening nucleic acid amplification tests for human immunodeficiency virus type 1 may require two different amplification targets. Transfusion 2012;52:431-439.
12. Müller B, Nübling CM, Kress J, Roth K, De Zolt S, Pichl L: How safe is safe: new HIV-1 variants missed by nucleic acid testing. Transfusion 2013;53(suppl 3):2422-2430.
13. Damond F, Roquebert B, Benard A, Collin G, Miceli M, Yeni P, Brun-Vezinet F, Descamps D: Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 2007;45: 3436-3438.
14. Wirden M, Tubiana R, Marguet F, Leroy I, Simon A, Bonmarchand M, Ait-Arkoub Z, Murphy R, Marcelin AG, Katlama C, Calvez V: Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J Clin Microbiol 2009;47:1543-1545.
15. Pyne MT, Brown KL, Hillyard DR: Evaluation of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test and identification of rare polymorphisms potentially affecting assay performance. J Clin Microbiol 2010;48:2852-2858.
16. Korn K, Weissbrich B, Henke-Gendo C, Heim A, Jauer CM, Taylor N, Eberle J: Single-point mutations causing more than 100-fold underestimation of human immunodeficiency virus type 1 (HIV-1) load with the Cobas TaqMan HIV-1 real-time PCR assay. J Clin Microbiol 2009;47:1238-1240.
17. Sizmann D, Glaubitz J, Simon CO, Goedel S, Buergisser P, Drogan D, Hesse M, Kroh M, Simmler P, Dewald M, Gilsdorf M, Fuerst M, Ineichen R, Kirn A, Pasche P, Wang Z, Weisshaar S, Young K, Haberhausen G, Babiel R: Improved HIV-1 RNA quantitation by COBAS AmpliPrep/COBAS TaqMan HIV-1 Test, v2.0 using a novel dual-target approach. J Clin Virol 2010;49:41-46.
18. Damond F, Avettand-Fenoel V, Collin G, Roquebert B, Plantier JC, Ganon A, Sizmann D, Babiel R, Glaubitz J, Chaix ML, Brun-Vezinet F, Descamps D, Rouzioux C: Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification. J Clin Microbiol 2010;49:1413-1416.
19. European Commission. Commission Decision of 3 February 2009 amending Decision 2002/364/EC on common technical specifications for in vitro-diagnostic medical devices (2009/108/EC). Official Journal of the European Union 2009; L39/34-L39/49.
20. Nübling CM, Unger G, Chudy M, Raia S, Löwer J: Sensitivity of HCV core antigen and HCV RNA detection in the early infection phase. Transfusion 2002;42:1037-1045.
21. Paul-Ehrlich-Institut. Bekanntmachung über die Zulassung von Arzneimitteln-Abwehr von Arzneimittelrisiken-Vom 15. Juni 2012. Anordnung von Auflagen zu den Zulassungen für zelluläre Blutkomponenten und gefrorene Frischplasmen, hier: Anordnung von Manahmen zur Risikominimierung beim Einsatz von HIV-1 NAT-Testsystemen. BAnz AT 2012; 2.09.2012 B6.